{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:21:44Z","timestamp":1793877704646,"version":"4.7.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00296-018-4201-3","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T04:06:25Z","timestamp":1542081985000},"page":"73-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-0988","authenticated-orcid":false,"given":"Gamze","family":"Kilic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4355-4356","authenticated-orcid":false,"given":"Erkan","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-0851","authenticated-orcid":false,"given":"Kemal","family":"Nas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-7250","authenticated-orcid":false,"given":"Ayhan","family":"Kamanl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3395-7178","authenticated-orcid":false,"given":"\u0130brahim","family":"Tekeoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"suppl 2","key":"4201_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):14\u201317. \n                    https:\/\/doi.org\/10.1136\/ard.2004.032482","journal-title":"Ann Rheum Dis"},{"key":"4201_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/1756-185X.12580","volume":"18","author":"K Nas","year":"2015","unstructured":"Nas K, Karkucak M, Durmus B, Karatay S, Capkin E, Kaya A, Ucmak D, Akar ZA, Cevik R, Kilic E, Kilic G, Ozgocmen S (2015) Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis 18:873\u2013879. \n                    https:\/\/doi.org\/10.1111\/1756-185X.12580","journal-title":"Int J Rheum Dis"},{"key":"4201_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263\u2013269. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(04)16676-2","journal-title":"Lancet"},{"key":"4201_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compan V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75:16\u201322. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-207526","journal-title":"Ann Rheum Dis"},{"key":"4201_CR5","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O\u2019Dwyer JL, Meads DM, Emery P, Conaghan PG, Helliwell PS (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386:2489\u20132498. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00347-5","journal-title":"Lancet"},{"key":"4201_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 77:3\u201317. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211734","journal-title":"Ann Rheum Dis"},{"key":"4201_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5606\/ArchRheumatol.2018.6946","volume":"33","author":"K Nas","year":"2018","unstructured":"Nas K, Kilic E, Cevik R, Bodur H, Ataman S, Ayhan F, Akgul O, Akinci A, Altay Z, Capkin E, Dagli AZ, Duruoz T, Gurer G, Gogus F, Garip Y, Kacar C, Kamanli A, Kaptanoglu E, Kaya T, Kocabas H, Ozdemirel EA, Ozel S, Sezer I, Sunar I, Yilmaz G (2018) Management of psoriatic arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions. Arch Rheum 33:108\u2013127. \n                    https:\/\/doi.org\/10.5606\/ArchRheumatol.2018.6946","journal-title":"Arch Rheum"},{"key":"4201_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-208337","journal-title":"Ann Rheum Dis"},{"key":"4201_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O\u2019Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060\u20131071. \n                    https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"key":"4201_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O\u2019Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM (2017) Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT Working Group. J Rheumatol 44:697\u2013700. \n                    https:\/\/doi.org\/10.3899\/jrheum.170150","journal-title":"J Rheumatol"},{"key":"4201_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/ard.2006.051706","volume":"65","author":"J Fransen","year":"2006","unstructured":"Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL (2006) Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:1373\u20131378. \n                    https:\/\/doi.org\/10.1136\/ard.2006.051706","journal-title":"Ann Rheum Dis"},{"key":"4201_CR12","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.3899\/jrheum.091172","volume":"37","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Tom BD, Mease PJ, Farewell VT (2010) Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 37:1892\u20131897. \n                    https:\/\/doi.org\/10.3899\/jrheum.091172","journal-title":"J Rheumatol"},{"key":"4201_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/rheumatology\/39.2.148","volume":"39","author":"G Eberl","year":"2000","unstructured":"Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS (2000) Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology 39:148\u2013155","journal-title":"Rheumatology"},{"key":"4201_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3899\/jrheum.150826","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates LC, Helliwell PS (2016) Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol 43:371\u2013375. \n                    https:\/\/doi.org\/10.3899\/jrheum.150826","journal-title":"J Rheumatol"},{"key":"4201_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48\u201353. \n                    https:\/\/doi.org\/10.1136\/ard.2008.102053","journal-title":"Ann Rheum Dis"},{"key":"4201_CR16","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986\u2013991. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-201341","journal-title":"Ann Rheum Dis"},{"key":"4201_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acr.22576","volume":"68","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5\u00a0years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken) 68:267\u2013274. \n                    https:\/\/doi.org\/10.1002\/acr.22576","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4201_CR18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673. \n                    https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"key":"4201_CR19","first-page":"511","volume":"24","author":"JA Husted","year":"1997","unstructured":"Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ (1997) Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 24:511\u2013517","journal-title":"J Rheumatol"},{"key":"4201_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/ard.2003.006296","volume":"63","author":"SP McKenna","year":"2004","unstructured":"McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63:162\u2013169","journal-title":"Ann Rheum Dis"},{"key":"4201_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"4201_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"4201_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"key":"4201_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62:965\u2013969. \n                    https:\/\/doi.org\/10.1002\/acr.20155","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4201_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69:1441\u20131447. \n                    https:\/\/doi.org\/10.1136\/ard.2009.122259","journal-title":"Ann Rheum Dis"},{"key":"4201_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"4201_CR27","first-page":"1159","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V (2007) Outcome measures in psoriatic arthritis. J Rheumatol 34:1159\u20131166","journal-title":"J Rheumatol"},{"key":"4201_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811\u2013818. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Ann Rheum Dis"},{"key":"4201_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.semarthrit.2017.10.021","volume":"47","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Coates LC (2018) Considerations for the definition of remission criteria in psoriatic arthritis. Semin Arthritis Rheum 47:786\u2013796. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.021","journal-title":"Semin Arthritis Rheum"},{"key":"4201_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/art.40391","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol 70:345\u2013355. \n                    https:\/\/doi.org\/10.1002\/art.40391","journal-title":"Arthritis Rheumatol"},{"key":"4201_CR31","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/acr.23172","volume":"69","author":"C Desthieux","year":"2017","unstructured":"Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scrivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L (2017) Determinants of patient\u2013physician discordance in global assessment in psoriatic arthritis: a multicenter European Study. Arthritis Care Res (Hoboken) 69:1606\u20131611. \n                    https:\/\/doi.org\/10.1002\/acr.23172","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4201_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/rheumatology\/kex183","volume":"57","author":"LJJ Mens van","year":"2018","unstructured":"van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP (2018) Residual disease activity in psoriatic arthritis: discordance between the rheumatologist\u2019s opinion and minimal disease activity measurement. Rheumatology (Oxford) 57:283\u2013290. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex183","journal-title":"Rheumatology (Oxford)"},{"key":"4201_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45:151\u2013158. \n                    https:\/\/doi.org\/10.1002\/1529-0131(200104)45:2%3C151::AID-ANR168%3E3.0.CO;2-T","journal-title":"Arthritis Rheum"},{"key":"4201_CR34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1136\/ard.2008.098202","volume":"68","author":"JA Husted","year":"2009","unstructured":"Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD (2009) Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis 68:1553\u20131558. \n                    https:\/\/doi.org\/10.1136\/ard.2008.098202","journal-title":"Ann Rheum Dis"},{"key":"4201_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","volume":"47","author":"ME Husni","year":"2017","unstructured":"Husni ME, Merola JF, Davin S (2017) The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 47:351\u2013360. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2017.05.010","journal-title":"Semin Arthritis Rheum"},{"key":"4201_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.reuma.2010.03.003","volume":"7","author":"M Freire","year":"2011","unstructured":"Freire M, Rodriguez J, Moller I, Valcarcel A, Tornero C, Diaz G, Armendariz Y, Paredes S (2011) Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7:20\u201326. \n                    https:\/\/doi.org\/10.1016\/j.reuma.2010.03.003","journal-title":"Reumatol Clin"},{"key":"4201_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","volume":"19","author":"LJJ Mens van","year":"2017","unstructured":"van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP (2017) Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther 19:226. \n                    https:\/\/doi.org\/10.1186\/s13075-017-1424-8","journal-title":"Arthritis Res Ther"},{"key":"4201_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3899\/jrheum.151101","volume":"43","author":"J Marin","year":"2016","unstructured":"Marin J, Acosta Felquer ML, Ferreyra Garrot L, Ruta S, Rosa J, Soriano ER (2016) Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol 43:907\u2013910. \n                    https:\/\/doi.org\/10.3899\/jrheum.151101","journal-title":"J Rheumatol"},{"key":"4201_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","volume":"77","author":"LJJ Mens van","year":"2018","unstructured":"van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251\u2013257. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211998","journal-title":"Ann Rheum Dis"},{"key":"4201_CR40","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42:1460\u20131468. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/keg384","journal-title":"Rheumatology"},{"key":"4201_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702\u2013709. \n                    https:\/\/doi.org\/10.1136\/ard.2008.092767","journal-title":"Ann Rheum Dis"},{"key":"4201_CR42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986. \n                    https:\/\/doi.org\/10.1002\/art.24403","journal-title":"Arthritis Rheum"},{"key":"4201_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/ard.2003.006775","volume":"63","author":"M Feletar","year":"2004","unstructured":"Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12-month observational study of 16 patients. Ann Rheum Dis 63:156\u2013161","journal-title":"Ann Rheum Dis"},{"key":"4201_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acr.22529","volume":"67","author":"A Haddad","year":"2015","unstructured":"Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD (2015) Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken) 67:842\u2013847. \n                    https:\/\/doi.org\/10.1002\/acr.22529","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4201_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10067-015-3035-6","volume":"35","author":"CL Overman","year":"2016","unstructured":"Overman CL, Kool MB, Da Silva JA, Geenen R (2016) The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol 35:409\u2013415. \n                    https:\/\/doi.org\/10.1007\/s10067-015-3035-6","journal-title":"Clin Rheumatol"},{"key":"4201_CR46","first-page":"1842","volume":"28","author":"KB Sokoll","year":"2001","unstructured":"Sokoll KB, Helliwell PS (2001) Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28:1842\u20131846","journal-title":"J Rheumatol"},{"key":"4201_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23571","author":"K Wervers","year":"2018","unstructured":"Wervers K, Vis M, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael J, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ, The behalf of C (2018) Burden of psoriatic arthritis in different definitions of disease activity: comparing minimal disease activity and disease activity index for psoriatic arthritis. Arthritis Care Res (Hoboken). \n                    https:\/\/doi.org\/10.1002\/acr.23571","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4201_CR48","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, Gladman DD (2014) Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 41:887\u2013896. \n                    https:\/\/doi.org\/10.3899\/jrheum.130797","journal-title":"J Rheumatol"},{"issue":"6 Suppl 43","key":"4201_CR49","first-page":"S","volume":"24","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S\u2013S83","journal-title":"Clin Exp Rheumatol"},{"key":"4201_CR50","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.151491","volume":"43","author":"S Brikman","year":"2016","unstructured":"Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol 43:1749\u20131754. \n                    https:\/\/doi.org\/10.3899\/jrheum.151491","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4201-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:16:02Z","timestamp":1573586162000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4201"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4201-3","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"6 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We have no conflicts of interest with respect to the authorship and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects in this study have been informed for the study protocol and written informed consents have been obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}